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The inhibitory neurotransmission mediated by gamma-aminobu-
tyric acid (GABA) is substantially involved in the regulation of 
anxiety, memory processes, muscle tone, vigilance, and epilep-
togenesis in the mammalian central nervous system (Rudolph and 
Möhler, 2004). In major part, these regulatory roles of GABA are 
exerted through activation of GABAA receptors, which most often 
comprise an α-subunit (α1-6), a β-subunit, and a γ subunit in a 
2:2:1 stoichiometry (McKernan and Whiting, 1996). The majority 
of GABAA receptors contain the benzodiazepine binding site, 
found at the interface between the γ2 subunit and either an α1, α2, 
α3, or α5 subunit. Through this binding site, GABAA receptors are 
susceptible to both positive and negative modulation (Olsen and 
Sieghart, 2008). Non-selective negative allosteric modulators (or 
inverse agonists), such as β-carbolines DMCM, and FG 7142, 
decrease the inhibitory effects of GABA, and have been known 
for many years to exert, nearly at the same time, the anxiogenic, 
proconvulsant, and cognition-enhancing actions in animals 
(Braestrup et al., 1982; Rossier et al., 1983). Thus, the highly 
desirable pro-cognitive potential of such modulators could not 
have been clinically verified and exploited (Dorow et al., 1983).
More recently, genetic studies pointed to the GABAA recep-
tors containing the α5 subunit as the major substrate of pro-cog-
nitive effects of reduction of GABAergic neurotransmission 
(Collinson et al., 2002; Crestani et al., 2002). Based on such data, 
development of compounds with selectivity for the α5 subtype of 
GABAA receptors, which may enhance cognitive performance 
without the side-effects associated with non-selective com-
pounds, has been initiated (Maubach, 2003) and resulted, among 
others, in several patents claiming the effectiveness of α5-
selective negative modulators in cognitive symptoms of schizo-
phrenia, Down syndrome, or mood disorders (Guerrini and 
Ciciani, 2013; Martínez-Cué et al., 2014). A couple of ligands 
(α5IA, RO4938581, RY-23, RY-24, PWZ-029) have been 
reported to demonstrate a considerable degree of affinity and/or 
efficacy selectivity for α5 GABAA receptors in vitro, coupled 
with enhancement of performance of different cognitive tasks, 
such as the delayed-match-to-position (Ballard et al., 2009; 
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Dawson et al., 2006) and the standard spatial version of water 
maze (Ballard et al., 2009), object retrieval task (Ballard et al., 
2009; Soto et al, 2013), or passive avoidance in animals (Savić 
et al., 2008), as well as prevention of alcohol-induced memory 
impairment in humans (Nutt et al., 2007). One such ligand is 
PWZ-029, a partial inverse agonist with both the binding and 
functional selectivity for α5-containing GABAA receptors, at 
which it reduces control current by 20% when applied at 1 µM. 
Devoid of effects on anxiety, muscle tone, or convulsion propen-
sity in the tested dose range (2–20 mg/kg), it improved passive 
avoidance learning task in normal rats (Savić et al., 2008). 
Moreover, PWZ-029 reversed the scopolamine-induced cogni-
tion impairment in novel object recognition, but not water maze 
task in rats (Milić et al., 2013), and attenuated scopolamine-
induced impairment of Pavlovian fear conditioned contextual 
memory in mice (Harris et al., 2008). The results of the latter 
kind of experiments, obtained in animals exposed to a compound 
that induces changes in neurotransmission reminiscent of patho-
logical processes are an improvement on those from tests using 
intact animals for the pro-cognitive potential of drug candidates 
(Keeler and Robbins, 2011). However, many of the models 
employed have limited construct validity and the end point 
behavioral assessment measures do not always translate well to 
the clinic for schizophrenia-spectrum disorders (Pratt et al., 
2012). In regard to other α5-selective inverse agonists, 
RO49838581 has been shown to ameliorate cognitive deficits in 
rats induced by subchronic and neonatal administration of phen-
cyclidine in novel object recognition and attentional set-shifting 
performance task, respectively (Redrobe et al., 2012).
Since its discovery, the N-methyl-d-aspartate (NMDA) 
receptor system for the main excitatory neurotransmitter gluta-
mate has been implicated in many essential functions, such as 
neuronal plasticity, neurotoxicity, learning, and memory (Riedel 
et al., 2003). Besides phencyclidine, dizocilpine (MK-801) is 
another experimentally widely used NMDA receptor antagonist, 
and MK-801-induced cognitive impairments have been vali-
dated as a rodent model related to human cognitive deficits asso-
ciated with dementia (Van der Staay et al., 2011) and 
schizophrenia (Adell et al., 2012; Andine et al., 1999). Although 
the MK-801-induced memory deficit model has been assessed 
as the second most commonly (after scopolamine) used deficit 
model in preclinical cognition research (Van der Staay et al., 
2011), the published results of testing the selective α5 GABAA 
receptor negative modulators in animals treated with MK-801 
are limited to only one study, using the incremental repeated 
acquisition task which allows for the assessment of effects on 
learning at various levels of task-difficulty (Povroznik et al., 
2014). Such data are expected to be of special relevance in the 
pursuit of novel therapies for cognitive aspects of neuropsychi-
atric disorders, beginning with the premise that α5 GABAA 
receptors located at the base of dendritic spines of pyramidal 
cells in the hippocampus and neocortex are strategically located 
to modulate excitatory glutamatergic input that arrives at the 
spines of these cells (Rudolph and Möhler, 2014).
The aim of the present study was to investigate the effects of 
PWZ-029 on the object recognition and social recognition mem-
ory, as well as the water maze performance affected by the lowest 
effective dose of MK-801 in rats (0.1 mg/kg); these three tests 
were selected in order to explore a wide range of cognitive 
domains (from visual and social recognition to spatial memory). 
Besides cognitive impairments, MK-801, administered in some-
what higher doses (0.2 mg/kg), has been validated to induce psy-
chosis, in concordance with the hypothesis of NMDA receptor 
hypofunction in schizophrenia (Neill et al., 2010; Olney et al., 
1999). Hence, we opted to also assess the potential of PWZ-029 
to reverse the MK-801- as well as the amphetamine-induced 
hyperlocomotion. Namely, it was reported that RO49838581 
antagonized the stimulating action of the hyperdopaminergic 
agent amphetamine in normal rats (Redrobe et al., 2012); such a 
finding with a negative modulator of α5 GABAA receptors seems 
to be at odds with the data that a positive modulator of the same 
receptors, SH-053-R-CH3-2’F (Savić et al., 2008), was also able 
to prevent the hyperlocomotor action of amphetamine in meth-
ylazoxymethanol acetate (MAM)-treated rats, expressing the 
schizophrenia-like phenotype (Gill et al., 2011). Finally, we per-
formed the pharmacokinetic study of PWZ-029 dosed at 5 mg/kg 
and estimated its free plasma and brain concentrations 20 min-
utes after administering the 2, 5, or 10 mg/kg dose in rats. These 
studies were aimed to assess if the in vivo concentrations attained 
at the time of behavioral testing enable a selective involvement of 
α5 GABAA receptors (cf. Obradović et al., 2014; Redrobe et al., 
2012), when compared with the in vitro findings of PWZ-029 
(Savić et al., 2008).
Material and methods
Drugs
PWZ-029 (molecular weight = 291.73 g/mol), an α5 GABAA 
receptor selective inverse agonist, was synthesized at the 
Department of Chemistry and Biochemistry, University of 
Wisconsin–Milwaukee, USA. Binding affinity for PWZ-029 at 
human recombinant GABAA receptors containing β3, γ2, and α1, 
α2, α3, or α5 subunit was determined to amount (Ki, nM): 920, > 
300, > 300 and 38.8, respectively (Harris et al., 2008; Savić et al., 
2008). (+)-MK-801 hydrogen maleate, a potent NMDA receptor 
antagonist, and d-amphetamine-sulfate were purchased from 
Sigma–Aldrich. PWZ-029 was suspended/dissolved with the aid 
of sonication in the solvent (85% distilled water, 14% propylene 
glycol, and 1% Tween 80). MK-801 and amphetamine were dis-
solved in saline. All compounds were administered intraperito-
neally (i.p.) in a volume of 2 mL/kg, 20 min before the behavioral 
testing, with the exception of Experiment V, in which the animal’s 
behavior was recorded immediately after respective treatments.
For plasma protein and brain tissue binding studies, stock 
solutions of PWZ-029 were prepared in dimethyl sulfoxide 
(DMSO).
Pharmacokinetic study of PWZ-029
Rats were divided in five groups which corresponded to predeter-
mined time intervals (5, 10, 20, 40, and 60 min), each containing 
three animals. PWZ-029, dosed at 5 mg/kg, was administered by 
i.p. injection in a volume of 2 mL/kg. Additional experiments 
were performed in order to determine brain and plasma concen-
tration, as well as to calculate free brain and plasma levels of 
PWZ-029 dosed at 2, 5, and 10 mg/kg, 20 min after i.p. injection. 
The blood samples were collected in heparinized syringes via 
cardiac puncture of rats anesthetized with ketamine solution 
(10% Ketamidor, Richter Pharma AG, Wels, Austria), dosed at 
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100 mg/kg (i.p.), and centrifuged at 2500 rpm for 10 min to 
obtain plasma. Thereafter, rats were decapitated and brains were 
weighed, homogenized in 5 mL of methanol and centrifuged at 
6000 rpm for 20 min. To determine the concentration of PWZ-
029 in plasma and supernatants of brain tissue homogenates, 
PWZ-029 was extracted from these samples by solid phase 
extraction, using Oasis HLB cartridges (Waters Corporation, 
Milford, MA). The procedure of sample preparation and determi-
nation of PWZ-029 by ultraperformance liquid chromatography–
tandem mass spectrometry (UPLC–MS/MS) with Thermo 
Scientific Accela 600 UPLC system connected to a Thermo 
Scientific TSQ Quantum Access MAX triple quadrupole mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA), equipped 
with electrospray ionization (ESI) source, was described in detail 
by Obradović et al. (2014).
Plasma protein and brain tissue binding 
studies
The rapid equilibrium dialysis assay used to determine free frac-
tion of PWZ-029 in rat plasma and brain tissue was the same as 
in Obradović et al. (2014).
Behavioral experiments
Experiments were carried out on nine weeks old (adults, 320 in 
total, weighing 200–250 g) or 21 days old (juvenile, 16 in total) 
outbred Wistar albino male rats supplied by Military Farm, 
Belgrade, Serbia. Adult rats were housed in Makrolon type III 
cages in groups of four and juvenile in groups of eight and had 
free access to food and water. The temperature of the animal 
room was 22 ± 1 °C, relative humidity 40–70%, illumination 120 
lx, with a 12 h light/dark cycle (lights on at 06:00 h). All experi-
ments took place during the light phase of the diurnal cycle 
(09:00–15:00 h). For social discrimination novelty procedure 
adults were isolated in individual cages two days before testing. 
The behavior was recorded by a ceiling-mounted camera and 
analyzed by ANY–maze Video Tracking System software 
(Stoelting Co., USA). Experiments were carried out in accord-
ance with the EEC Directive 86/609 and were approved by the 
Ethical Committee on Animal Experimentation of the Faculty of 
Pharmacy in Belgrade. Throughout the study, experimentally 
naïve animals were used.
Novel object recognition test
The protocol and statistical analysis used for the novel object rec-
ognition test (NORT) were in accordance with those given by 
Bevins and Besheer (2006), and have been described in detail by 
Milić et al. (2013). The apparatus consisted of a rectangular 
chamber (65 cm × 45 cm × 45 cm) which was illuminated with 
indirect white lighting (20 lx). Animals were habituated to an 
empty chamber for 10 min, 24 h before the beginning of experi-
ment. The NORT was divided in two stages: familiarization (T1) 
and testing (T2). In the familiarization phase two identical objects 
were placed 10 cm from the sides of the chamber and 25 cm 
apart. Twenty minutes after receiving appropriate treatment, each 
rat was placed in the arena between the two objects facing the 
opposite wall and allowed to explore them for 5 min. Animal was 
then removed from the apparatus and returned to the cage for 1 h. 
To test for object recognition, one of the familiar sample objects 
was replaced with a novel object and animal was returned to the 
apparatus and allowed to explore for 3 min. Object exploration 
was recorded when the animal was in close proximity (2 cm or 
less) and oriented to the object, and if the animal sniffed or pawed 
the object. Furthermore, the animals that did not explore both 
objects for a minimum of 2 s each were excluded from the data 
analyses. Object set consisted of a semi–transparent pyramid 
(base 8 cm × 8 cm, height 7 cm) and a nontransparent dome–
shaped paperweight (base diameter 9 cm, height 10 cm), which 
could not be displaced by rats. Each object was available in trip-
licate and all combinations and locations of objects were used in 
a balanced manner to reduce potential biases. After each trial, the 
apparatus and objects were cleaned with 70% ethanol to reduce 
olfactory cues.
In Experiment I, the influence of PWZ-029 (2, 5 or 10 mg/kg) 
on MK-801-induced memory impairment in NORT was exam-
ined. The dose of MK-801 (0.1 mg/kg) was selected based on our 
preliminary study (unpublished data), which is in accordance with 
previous findings (De Lima et al., 2005; Van der Staay et al., 
2011). There were five groups of rats which received one of the 
following treatments before the familiarization phase: saline + 
solvent (N = 23), MK-801 (0.1 mg/kg) + solvent (N = 20) and 
MK-801 (0.1 mg/kg) in combination with PWZ-029 (2, 5, and 10 
mg/kg, N = 16, 17, and 19, respectively). The amount of time 
exploring two identical objects during T1 (Ta and Tb) and familiar 
(Tf) and novel (Tn) objects in T2 was automatically scored, and 
discrimination index ((Tn –Tf)/(Tf + Tn)) were calculated. The 
effect of treatment on exploratory behavior was assessed by inves-
tigating total exploration times in T1 (Ta + Tb) and T2 (Tf + Tn).
Social novelty discrimination procedure
Social novelty discrimination (SND) experiments compared the 
social investigation times of an adult rat with a familiar and a 
novel juvenile rat. The procedure is replicated from previous 
studies (Engelmann et al., 1995; Terranova et al., 2005). Testing 
consisted of two consecutive juvenile presentations periods to an 
adult subject: period 1 (P1) and period 2 (P2). At the beginning of 
P1, one juvenile was placed into the adult home cage and the time 
spent by the adult investigating the juvenile (anogenital sniffing, 
licking, close pursuing, and pawing) was recorded manually for 
5 min. During P2, the same juvenile and a second, novel juvenile 
were placed in the cage together with the adult, and the times 
spent by the adult investigating each juvenile were measured 
independently for 5 min. A different pair of juvenile rats was pre-
sented to each adult tested. Manual scoring was conducted in a 
blinded manner. We used a pharmacological deficit protocol, in 
which SND was impaired by pharmacological intervention, P1 
was 30 min, and there was no delay between P1 and P2. In such 
conditions, SND was expected to be high in control rats, while 
disrupted by MK-801 (0.1 mg/kg, i.p.), administered 20 min 
before P1.
In Experiment II, the influence of PWZ-029 (2, 5 or 10 mg/
kg) on MK-801-induced impairment in SND was examined. The 
dose of MK-801 (0.1 mg/kg) was selected based on our prelimi-
nary study (unpublished data). There were five groups of rats 
(N = 6 per each treatment group) which received one of the fol-
lowing treatments 20 min before P1: saline + solvent, MK-801 
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(0.1 mg/kg) + solvent, and MK-801 (0.1 mg/kg) in combination 
with PWZ-029 (2, 5, and 10 mg/kg). The amount of time investi-
gating familiar (Tf) and novel (Tn) juvenile during P2 was manu-
ally scored, and discrimination ratio (Tn/Tf) was calculated. 
Total exploration time during P1 and P2 was also manually 
recorded.
Morris water maze (MWM)
Experiments were performed in a 2 m diameter circular pool 
filled to a height of 30 cm with water at 22 ± 1 °C. The escape 
platform (15 cm × 10 cm) of the same color as the pool was sub-
merged 2 cm below the water surface. An indirect illumination 
(20 lx) in the experimental room was provided by white neon 
tubes fixed on the walls and many distal cues were present. On 
each of the five consecutive days rats were given one swimming 
block, consisting of four trials. For each trial the rat was placed in 
the water facing the pool at one of four pseudo–randomly deter-
mined starting positions. Since the platform was hidden in the 
middle of the NE quadrant during training sessions, the four dis-
tal start locations were: S, W, NW, and SE. Once the rat has found 
and mounted the escape platform it was permitted to remain on 
the platform for 15 s. The rat was guided to the platform by the 
experimenter if it failed to locate it within 120 s. During 
the acquisition phase, treatments were applied once daily before the 
swimming block. On the sixth day, rats were given a treatment-
free probe test (60 s) without the platform. In order to ensure that 
any spatial bias is a consequence of the spatial memory of escape 
location, rather than of a specific swim strategy, the probe test 
was started from the novel, most distant SW location (Vorhees 
and Williams, 2014).
In Experiment III we tested the effects of PWZ-029 on 
MK-801-induced memory impairment; the dose of MK-801 (0.1 
mg/kg) was selected as the lowest dose that disrupted acquisition 
in our water maze setting (unpublished data). The rats were 
divided into five groups which received one of the following 
treatments 20 minutes before swimming at each of five learning 
days: saline + solvent (N = 8), MK-801 (0.1 mg/kg) + solvent 
(N = 8), and combination of MK-801 (0.1 mg/kg) and PWZ-029 
(2, 5, and 10 mg/kg; N = 7, 8, and 8, respectively). The pool was 
virtually divided into four quadrants, three concentric annuli and 
a target region consisting of the intersection of the platform quad-
rant and the platform (middle) annulus, as represented in Savić 
et al. (2009). Dependent variables chosen for tracking during the 
acquisition trials were: escape latency (s), total distance traveled 
(m), mean speed (m/s) and path efficiency (the ratio of the short-
est possible path length to actual path length). The selected 
parameters in the probe test were the time in the target zone (s) 
and the time spent in the peripheral ring (s).
Locomotor activity (LA)
Activity of single rats in a clear Plexiglas chamber (40 × 25 × 35 
cm3) under dim red light (20 lx) was recorded for a total of 60 
min, without any habituation period but with 20 min of acclima-
tization to testing room, using ANY-maze software for MK-801-
induced hyperlocomotion. Different doses of PWZ-029 (2, 5, and 
10 mg/kg) and MK-801 (0.2 mg/kg) were applied 20 min before 
testing. The same apparatus was used for amphetamine-induced 
locomotor activity but different protocol was used. In this behav-
ioral test rats received appropriate treatment (solvent, saline, 2, 5, 
and 10 mg/kg PWZ-029) and were immediately placed in LA 
arena. Behavior was recorded for 20 min and then rats were 
injected with saline or 0.5 mg/kg amphetamine and locomotor 
activity was recorded for an additional 60 min.
The influence of 2, 5, and 10 mg/kg PWZ-029 on hyperloco-
motion induced by 0.2 mg/kg MK-801 was assessed in 
Experiment IV (treatment groups: saline + solvent (N = 9), 
MK-801 (0.2 mg/kg) + solvent (N = 8), and MK-801 (0.2 mg/kg) 
in combination with PWZ-029 (2, 5, and 10 mg/kg, N = 9, 9, and 
8, respectively)). Finally, the influence of PWZ-029 (2, 5, and 10 
mg/kg) on amphetamine-induced hyperactivity was assessed in 
Experiment V (treatment groups: saline + solvent (N = 8), 
amphetamine (0.5 mg/kg) + solvent (N = 8) and amphetamine 
(0.5 mg/kg) in combination with PWZ–029 (2, 5, and 10 mg/kg, 
N = 10, 7 and 7, respectively)).
Statistics
All numerical data presented in the figures are given as the mean 
± SEM, except for discrimination ratio where data are given as 
median with interquartile range. Pharmacokinetic parameters 
were calculated using PK Functions for Microsoft Excel software 
(by Joel Usansky, Atul Desai, and Diane Tang-Liuwere). In 
NORT, the differences between exploration times spent with 
familiar and novel object for each group were evaluated using 
Student’s paired t-test and two-way analysis of variance 
(ANOVA). Discrimination index was assessed by one-way 
ANOVA and one-sample t-test per treatment group. In SND pro-
cedure the discrimination ratios were analyzed by Kruskal–Wallis 
test, and significant results were further analyzed by a Student–
Newman–Keuls (SNK) multiple comparison test. Total explora-
tion times from NOR test and SND procedure were assessed by 
one-way ANOVA. The data from the acquisition days in the 
Morris water maze were averaged for each rat (total data/total 
number of trials per day) and analyzed using two-way ANOVA 
with repeated measures (factors: treatment and days) with days as 
the repeated measure. In the case of significant interaction, sepa-
rate one-way ANOVAs were conducted to assess the influence of 
treatment within individual levels of factor Days. The data from 
the probe test were assessed using one-way ANOVA. In LA test 
one-way ANOVA (for overall effect) or two-way ANOVA with 
repeated measures (factors: treatment and time) with time as the 
repeated measure (for effect during 5-min bins) were applied. 
Post hoc comparisons, where applicable, were performed using 
SNK test. Statistical analysis was performed using SigmaPlot 11 
(Systat Software Inc., Richmond, USA) software. Differences 
were considered significant when p < 0.05, while 0.1 > p > 0.05 
was considered as a trend toward significance.
Results
Pharmacokinetic and free fraction study of 
PWZ-029
The concentration–time profile of PWZ-029 in rat plasma and 
brain after intraperitoneal administration of 5 mg/kg dose, with 
the calculated pharmacokinetic parameters, is given in Figure 1.
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The concentrations of PWZ-029 in rat plasma (nmol/L) and 
brain tissue (nmol/kg), both total and free (estimated), obtained 
20 min after i.p. injection of PWZ-029 (dosed at 2, 5, and 10 mg/
kg) are shown in Table 1. Free concentrations of PWZ-029 were 
calculated by multiplying the measured total plasma and brain 
concentrations with the appropriate free fractions (23.95% for 
plasma and 7.91% for brain tissue) determined by rapid equilib-
rium dialysis.
The estimated free PWZ-029 brain concentrations, purpose-
fully presented as volume concentrations (Rempp et al., 1994), 
were incorporated in concentration–effects curves given in Savić 
et al. (2008), depicting the modulation of GABA-elicited cur-
rents by PWZ-029 on Xenopus oocytes expressing rat recombi-
nant α1-, α2-, α3-, and α5β3γ2 GABAA receptors (Figure 2).
Novel object recognition test
For Experiment I, the effects of MK-801 + PWZ-029 combina-
tion on the rats’ behavior in the NORT are presented in Figure 3. 
Paired t-test revealed no significant differences between the time 
that rats spent exploring two identical objects (object A and B) in 
T1 (data not shown). The same statistical analysis applied on the 
time spent in exploring the familiar and the novel object during 
T2 showed that only the control group and the group treated with 
combination 0.1 mg/kg MK-801 and 5 mg/kg PWZ-029 spent 
significantly more time in exploring the new object (t = 2.383, 
p = 0.026; t = 3.489, p = 0.003, respectively, Figure 3(a)). 
Similarly, discrimination indices were significantly different from 
zero (i.e. chance level) for the control group (t = 2.446; p = 0.023) 
and the group treated with the same combination (t = 4.220; 
p < 0.001; Figure 3(b)), notwithstanding the fact that one-way 
ANOVA revealed no significant difference in this parameter 
between treatment groups (F(4,90) = 1.85, p = 0.126). One-way 
ANOVA was significant for total exploration time in T1 (F(4,90) 
= 6.05, p < 0.001), and SNK post hoc revealed differences 
between control and all other treatment groups (p < 0.01 in all 
four cases). One-way ANOVA for total exploration time in T2 
was not significant (F(4,90) = 0.96, p < 0.435). Two-way ANOVA 
for exploration times (new vs. familiar) revealed a significant 
effect for factor object (F(1,180) = 8.44, p < 0.004), but not for 
treatment as a factor (F(4,180) = 1.04, p = 0.389), or interaction 
(F(4,180) = 1.26, p = 0.286).
To assess the replicability of our findings (cf. Loscalzo, 2012), 
especially having in mind that only the middle dose of PWZ-029 
was effective in NORT, we opted to perform an additional experi-
ment, as presented in Supplementary material.
Social novelty discrimination
In the SND test, there were no significant differences in total 
investigation times during the first 5 min of both P1 (one-way 
ANOVA: F(4,25) = 1.02, p = 0.414) and P2 (one-way ANOVA: 
F(4,25) = 0.45, p = 0.774, Figure 4). Following an extended P1 
period of 30 min and no delay between P1 and P2, subjects 
administered with vehicle spent more time investigating the 
novel juvenile than the familiar one, giving a high novel/familiar 
discrimination ratio, which represents a relatively good ability to 
socially discriminate (Figure 4). Kruskal–Wallis test revealed 
significant differences between treatment groups in regard to dis-
crimination ratios (H(4) = 12.378, p = 0.015). The administration 
of MK-801, irrespective of absence (saline) or presence of PWZ-
029 (2, 5 and 10 mg/kg) significantly decreased the discrimina-
tion ratio when compared to control rats (p < 0.05 for all treatment 
groups), as shown by SNK post hoc test.
Morris water maze
The results of two-way repeated measures ANOVA and SNK 
post hoc tests for Experiment III are given in Table 2; signifi-
cant effects of factor treatment and factor days were observed 
during acquisition for all parameters measured. After the post 
hoc analysis was performed, it appeared that all groups treated 
with MK-801, irrespective of absence (saline) or presence of 
PWZ-029 (2, 5, and 10 mg/kg), had longer escape latencies 
when compared to the control group (respective p values: p < 
0.001, p = 0.035, p = 0.002, and p < 0.001; Figure 5(a)), and 
similarly had traveled longer distances (respective p values: p < 
0.001, p = 0.005, p = 0.004, and p = 0.006; Figure 5(b)). 
Interestingly, post hoc analysis of the latency to reach the plat-
form also revealed a significant difference between groups 
Figure 1. Plasma and brain concentration–time profiles of PWZ-029  
(5 mg/kg) after intraperitoneal administration (n = 3 per time point).
Table 1. Total and estimated free concentrations of PWZ-029 (dosed at 2, 5, and 10 mg/kg) in plasma and brain samples after 20 min.
Dose (mg/kg) 2 5 10
Plasma (nmol/L) Total 4647.93 ± 880.16 11943.70 ± 2878.27 20087.07 ± 3997.23
Free 1113.18 ± 210.80 2860.51 ± 689.35 4810.85 ± 957.34
Brain (nmol/kg) Total 2323.12 ± 129.98 4074.59 ± 923.30 7002.81 ± 1505.01
Free 183.76 ± 10.28 322.30 ± 73.03 553.92 ± 119.05
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treated with the combination of 0.1 mg/kg MK-801 and 2 mg/
kg PWZ-029 and those treated with 0.1 mg/kg MK-801 in com-
bination with solvent (p = 0.022) or 10 mg/kg PWZ-029 (p = 
0.042), suggesting that the lowest dose of PWZ-029 exhibited a 
partial reversal of MK-801-induced impairment. Moreover, 
two-way ANOVA for mean speed showed significant effect for 
treatment, but post hoc revealed that only combination of 10 
mg/kg PWZ-029 and 0.1 mg/kg MK-801 swam slower than 
control rats (p = 0.028; Figure 5(c)). Rats treated with MK-801 
had lower path efficiencies compared to the control group (p < 
0.001); the addition of PWZ-029 (2, 5, and 10 mg/kg) did not 
significantly influence this parameter (respective p values: 
0.002, <0.001, and <0.001; Figure 5(c)).
One-way ANOVA applied on results from probe test revealed 
a significant influence of treatment on both parameters meas-
ured: the time spent in the target region (F(4,34) = 8.67, p < 
0.001; Figure 6(a)), and the time spent in the peripheral ring 
(F(4,34) = 5.99, p = 0.001; Figure 6(b)). Rats treated either with 
MK-801 or with combination of MK-801 and PWZ-029 (2, 5, 
and 10 mg/kg) spent less time in the target region (p < 0.001, p < 
0.001, p < 0.001, and p < 0.001, respectively) and more time 
searching in the peripheral ring (p = 0.002, p = 0.002, p = 0.002, 
and p = 0.003, respectively), when compared to control rats.
Locomotor activity
One-way ANOVA applied on data from Experiment IV has 
shown a statistically significant effect of treatment (F(4,38) = 
42.34, p < 0.001), and post hoc comparisons revealed highly sig-
nificant (p < 0.001) differences between all treatment groups (0.2 
mg/kg MK-801 alone and in combination with 2, 5, or 10 mg/kg 
PWZ-029) and control rats. Additionally, there was a significant 
difference between the MK-801 group and the MK-801 + PWZ-
029 (10 mg/kg) group (p = 0.012, Figure 7(a)). Analysis of dis-
tance traveled in 5-min bins revealed a significant effect of factor 
treatment and time (treatment: F(4,38) = 42.34, p < 0.001; time: 
F(11,418) = 15.514, p < 0.001; interaction F(44,418) = 0.960, p = 
0.547; Figure 7(b)).
Figure 3. The effects of 0.1 mg/kg MK-801 (MK-801 0.1 + SOL) and combination of 0.1 mg/kg MK-801 and PWZ-029 (2, 5, and 10 mg/kg) on 
the time exploring familiar and novel object in T2 (a) and on discrimination index (b) in novel object recognition test. Data are represented as 
mean + SEM. *p < 0.05 and **p < 0.01 for the familiar vs. novel exploration times (paired-samples t-test). A significant difference from zero for 
discrimination index is indicated with # (one sample t-test, #p < 0.05, ###p < 0.001). Number of animals per treatment, for SAL + SOL through MK-
801 0.1 + PWZ-029 10, respectively: 23, 20, 16, 17, and 19. SAL = saline, SOL = solvent.
Figure 2. The approximated electrophysiological responses of 
estimated free PWZ-029 brain concentrations (given in Table 1), 
presented on the concentration-response curves of PWZ-029 at rat 
recombinant α1-, α2-, α3,- and α5β3γ2 GABAA receptors given in 
Savić et al. (2008).
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In Experiment V, the tendency of decreasing the locomotor 
activity by the investigated doses of PWZ-029 on their own did 
not reach significance (one-way ANOVA for total distance 
traveled in first 20 min: F(3,28) = 2.73, p = 0.063). One-way 
ANOVA applied on the overall data from 60 min recordings after 
amphetamine was injected revealed a significant effect on total 
distance traveled (F(4,35) = 8.01, p < 0.001); post hoc results are 
given in Figure 8(a). Two-way repeated measures ANOVA, 
applied to 5-min bins, confirmed that amphetamine-treated rats 
pretreated with any of three doses of PWZ-029 traveled nearly 
the same distance as those pretreated with vehicle (treatment: 
F(4,35) = 8.01, p < 0.001, time: F(11,385) = 5.06, p < 0.001, 
interaction: F(44,385) = 1.17, p = 0.216; Figure 8(b)).
Discussion
In the present study, the NMDA receptor hypofunction induced 
by MK-801, usually seen as a model of memory impairment and 
psychotic-like behaviors, exerted reliable deficits in three varied 
cognitive tasks in rats. Our results reveal that negative modula-
tion of α5 GABAA receptors was able to prevent only certain 
aspects of such cognitive disruption. While beneficial effects of 
PWZ-029 on deficit in hippocampus-dependent spatial learning 
in the Morris water maze appeared to be partial, and confined to 
the lowest dose used (2 mg/kg) and the acquisition phase, in 
NOR test, which predominantly measures visual recognition 
memory as a type of declarative memory (Young et al., 2009), 5 
mg/kg PWZ-029 completely reversed MK-801-induced cogni-
tive deficits. The latter finding was replicated in an additional 
experiment.
Van der Staay et al. (2011) demonstrated that 0.1 mg/kg 
MK-801 can reduce the total time the rats spent exploring the 
objects during T1 in the NOR test. Decrease of total exploration 
time during familiarization phase observed in our study further 
suggests that MK-801-induced deficits with 0.1 mg/kg cannot 
be seen as unambiguously selective for cognition, and empha-
sizes the necessity for discussing possible motivational and sen-
sorimotor changes. Taking into account the evidence that lack of 
α5 GABAA receptors could itself produce sensorimotor distur-
bances (Hauser et al., 2005) it is not surprising to see decreased 
exploration times in combination (MK-801 and PWZ-029) 
groups even during T2, as presented for the additional 
Figure 4. The effects of 0.1 mg/kg MK-801 (MK-801 0.1 + SOL) and 
combination of 0.1 mg/kg MK-801 and PWZ-029 (2, 5, and 10 mg/kg) on 
discrimination ratio and total exploration time in P2 in SND procedure. 
A significant difference is indicated with *(SNK multiple comparison 
after Kruskal–Wallis test, p < 0.05). Data are represented as median ± 
(25–75%). Number of animals per each treatment group was 6.  
SAL = saline, SOL = solvent.
Table 2. The effects of MK-801 and PWZ-029 administration on the rat’s behavior in the MWM. Two-way repeated measures ANOVA and overall post 
hoc results for latency (s), total distance (m), mean speed (m/s), and path efficiency.
Two–way repeated measures ANOVA
Factor Latency Total distance Mean speed Path efficiency
Treatment: F(4,34) 9.497 5.847 3.341 10.431
p <0.001 0.001 0.021 <0.001
Days: F(4,136) 33.248 26.229 1.592 19.729
p <0.001 <0.001 0.180 <0.001
Interaction: F(12,136) 1.410 0.662 1.157 2.100
p 0.410 0.826 0.311 0.481
SNK post hoc for treatment
MK + SOL vs. SAL + SOL <0.001 <0.001 ns <0.001
MK + PWZ 2 vs. SAL + SOL 0.035 0.005 ns 0.002
MK + PWZ 5 vs. SAL + SOL 0.002 0.004 ns <0.001
MK + PWZ 10 vs. SAL + SOL <0.001 0.006 0.028 <0.001
MK + PWZ 2 vs. MK + SOL 0.022 ns ns ns
MK + PWZ 5 vs. MK + SOL ns ns ns ns
MK + PWZ 10 vs. MK + SOL ns ns ns ns
MK + PWZ 2 vs. MK + PWZ 5 ns ns ns ns
MK + PWZ 2 vs. MK + PWZ 10 0.042 ns ns ns
SAL: saline; SOL: solvent; MK: 0.1 mg/kg MK-801; PWZ 2: 2 mg/kg PWZ-029; PWZ 5: 5 mg/kg PWZ-029; PWZ 10: 10 mg/kg PWZ-029; ns: not significant.
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experiment (see Supplementary material online). Nevertheless, 
a significant correlation between the time spent investigating 
two identical objects in T1 and the degree of preference for a 
novel object does not exist (Gaskin et al., 2010), and any reduc-
tion in exploratory activity in treatment groups cannot decisively 
affect the cognitive ability of the rat. Similarly, non-cognitive 
influences may also have contributed to the observed differences 
in two experiments when the exploration times of the novel vs. 
old object during T2 were assessed by two-way ANOVA of 
absolute values, but not by the statistical analysis of the discrim-
ination index, as a relative measure of discrimination that cor-
rects for activity and thus is less biased toward any factors 
affecting exploration, including those related to the sensorimo-
tor performance (Akkerman et al., 2012).
It is notable that PWZ-029 dosed at 5 mg/kg also enhanced 
formation of declarative memory in normal rats, assessed through 
the passive avoidance test (Savić et al., 2008). On the other hand, 
recognition memory deﬁcits in the SND procedure, which 
engages different brain regions (Watson et al., 2012), were not 
affected by negative modulation of α5 GABAA receptors. Motor 
hyperactivity induced with 0.2 mg/kg MK-801, reflecting posi-
tive symptoms of schizophrenia (Andine et al., 1999), was sus-
ceptible to only slight attenuation by PWZ-029, dosed at 10 mg/
kg but not 2 and 5 mg/kg. Hyperlocomotion after acute adminis-
tration of amphetamine was unaffected by previous application 
of 2, 5, or 10 mg/kg PWZ-029, which is notably different than in 
the study with RO4938581, another α5-selective negative modu-
lator (Redrobe et al., 2012). Nonetheless, in the latter study, 
Figure 5. The effects of addition of PWZ-029 (2, 5, and 10 mg/kg) to 0.1 mg/kg MK-801 on the latency to reach the platform (a), the total 
distance (b), mean speed (c), and the path efficiency (d) during the learning phase of Experiment III. Each data point represents the mean of 
average values calculated for each rat for the respective day. Number of animals per treatment, for SAL + SOL through MK-801 0.1 + PWZ 10, 
respectively: 8, 8, 7, 8, and 8. SAL = saline, SOL = solvent, PWZ = PWZ-029.
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complete prevention of this behavioral effect of amphetamine 
was far from accomplished by negative GABAA receptor modu-
lation (Redrobe et al., 2012), suggesting that possible trials aimed 
to ameliorate positive symptoms by such an approach would give 
results which are inferior to those attainable by standard antipsy-
chotic treatment (e.g. Sun et al., 2009).
The calculated pharmacokinetic parameters indicated that 
PWZ-029 reaches high concentrations in plasma and brain tissue, 
with relatively fast elimination rate. The approximated electro-
physiological responses (Figure 2) of estimated free PWZ-029 
brain concentrations (Table 1) suggested that PWZ-029 at 1 µM, 
which is the concentration roughly twice higher than free brain 
concentration after the 10 mg/kg dose, could elicit maximally 
20% and 15% potentiation at α3β3γ2 receptors and α1β3γ2 recep-
tors, respectively. For comparison, the standard non-selective 
neutral modulator flumazenil exhibits at 1 µM as much as 56% 
and 30% of positive modulation at α3β3γ2 and α2β3γ2 receptors, 
respectively, without significant effects at α1β3γ2 receptors 
(Ramerstorfer et al., 2010). Having also in mind that modulation 
of control GABA currents by 1 µM PWZ-029 at α3β3γ2 and 
α1β3γ2 receptors constitutes no more than 3% and 7%, respec-
tively, of maximum modulation by diazepam, the prototypic 
positive modulator (personal communication, W. Sieghart), it 
seems unlikely that partial positive modulation by PWZ-029 on 
α3 or α1 GABAA receptors would induce noticeable behavioral 
consequences. However, it cannot be ruled out that even slight 
modulation by PWZ-029 at receptors other than those containing 
the α5 subunit may have some influence on the behavioral 
changes elicited by MK-801. In regards to modulation by 1 µM 
PWZ-029 at α5β3γ2 receptors, it amounts to approximately 40% 
and more than 100% of the maximum negative modulation by the 
prototypic full negative modulator DMCM and the partial nega-
tive modulator FG7142, respectively (personal communication, 
W. Sieghart), and is thus expected to determine the behavioral 
profile of PWZ-029 (Savić et al.,2008).
Apparently, while PWZ-029, in the dose range between 2 and 
10 mg/kg, did not exert marked differences in selectivity at ben-
zodiazepine-sensitive GABAA receptors, differences in its 
behavioral outputs in cognitive tasks were clearly manifested. 
This may mean that modest changes in negative modulation of α5 
GABAA receptors, in the settings of NMDA receptor dysfunction 
elicited by the dose of 0.1 mg/kg MK-801, can give rise to much 
more complex variability in behavioral outcomes. In freely mov-
ing rats, acute i.p. injection of MK-801 (0.1–0.2 mg/kg) increased 
the neuron firing rates and gamma-band amplitude, while 
decreased neuronal synchronization in the medial prefrontal cor-
tex, one of the cortical regions most consistently implicated in 
the etiology of schizophrenia (Molina et al., 2014). In a similar 
electrophysiological analysis of neuronal activity in medial pre-
frontal cortex of rats after a single 0.1 mg/kg dose of MK-801, it 
was found that blockade of NMDA receptors results in excitation 
of pyramidal neuron activity, which was most probably indirectly 
caused by inhibition of GABA interneurons through blockade of 
highly sensitive NMDA receptors which they express (Homayoun 
and Moghaddam, 2007).
In settings of NMDA blockade-induced increased excita-
tion, therefore, it may be expected that PWZ-029-mediated 
negative modulation of α5 GABAA receptors, with reduction of 
the amplitudes of the inhibitory postsynaptic potentials (cf. 
data for another α5-selective negative modulator, IAα5, given 
in Ali and Thomson, 2008), leads to further neuronal desyn-
chronization and deterioration of cognitive and other behavio-
ral functions in rats. However, in behavioral paradigms used in 
our study, PWZ-029 either exhibited no effect (SND) or 
improved MK-801-induced deficit, slightly to moderately 
(MWM and LA), or completely (NORT). A similar finding in 
NORT was also observed with RO4938581, another α5-
selective negative modulator, administered to rats exposed to 
phencyclidine (Redrobe et al., 2012). Furthermore, we reported 
that PWZ-029 may induce dose-dependent hypolocomotion in 
rats, significant at the dose of 10 mg/kg, and susceptible to 
antagonism by flumazenil as a non-selective, but not βCCt as 
an α1-selective neutral modulator (Savić et al., 2008); such an 
effect of PWZ-029 cannot be easily related to diminished inhi-
bition, i.e. excitation.
Figure 6. The effects of addition of PWZ-029 (2, 5, and 10 mg/kg) to 
0.1 mg/kg MK-801 on the time spent in the target zone (a) and the 
time spent in the peripheral ring (b) during the probe test. **p < 0.01 
and ***p < 0.001 compared to control (SAL + SOL) group. All data are 
presented as the mean + SEM. Number of animals per treatment, for 
SAL + SOL through MK-801 0.1 + PWZ-029 10, respectively: 8, 8, 7, 8, 
and 8. SAL = saline, SOL = solvent.
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Receptors containing the α5 subunit are substantially 
expressed in brain regions such as the hippocampus, the olfactory 
bulb and deeper layers of the neocortex (Pirker et al., 2000; 
Sieghart and Sperk, 2002), and are located at extrasynaptic, but 
also synaptic sites (Serwanski et al., 2006). With respect to the 
synaptic population of α5 GABAA receptors, they are predomi-
nantly found at distal dendritic locations at pyramidal neurons 
(Ali and Thomson, 2008), but also at inhibitory interneurons, at 
Figure 7. The effects of addition of 2, 5, and 10 mg/kg PWZ-029 to 0.2 mg/kg MK-801 on the total distance traveled (a) and on distance traveled 
in 5-min bins (b) during 60 min in LA. ***p < 0.001 compared to control (SAL + SOL) group; +p < 0.05 compared to 0.2 mg/kg MK-801 (MK-801 
0.2) group. All data are presented as the mean +/± SEM. Number of animals per treatment, for SAL + SOL through MK-801 0.1 + PWZ-029 10, 
respectively: 9, 8, 9, 9, and 8. SAL = saline, SOL = solvent.
Figure 8. The influence of addition of 2, 5, and 10 mg/kg PWZ-029 to 0.5 mg/kg amphetamine on the total distance traveled during 60 min after 
amphetamine was injected (a) and on distance traveled in 5-min bins during all testing (b) in LA test. **p < 0.01 and ***p < 0.001 compared to 
control (SAL + SAL or SOL + SAL) group. All data are presented as the mean ± SEM. Number of animals per treatment, for SOL + SAL through PWZ-029 
10 + AMPH 0.5, respectively: 8, 8, 10, 7, and 7. SAL = saline, SOL = solvent, AMPH = amphetamine.
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least in the hippocampus of an adult rat (Salesse et al., 2011). It 
was shown that the negative α5-selective allosteric modulator 
L655,708, unexpectedly, can decrease the discharge rates of neo-
cortical neurons during episodes of ongoing neuronal activity, in 
the manner similar to diazepam (Drexler et al., 2013). As proof of 
receptor selectivity, the excitatory-like action of the α5-selective 
positive modulator SH-053-2’F-R-CH3 was absent in brain 
slices from α5(H105R) mice, devoid of the benzodiazepine bind-
ing site at α5 GABAA receptors (Drexler et al., 2013). All of these 
data together suggest that modulation of α5 GABAA receptors, 
present in pyramidal neurons but also interneurons, elicits the 
consequences at the electrophysiological and behavioral levels 
which are not a mere fraction of the sum of effects otherwise seen 
when all four populations of benzodiazepine-sensitive GABAA 
receptors are modulated (cf. Zarnowska et al., 2009). It seems 
possible that one sub-population of α5 GABAA receptors is 
expressed in a position privileged to control the activity of inhibi-
tory interneurons projecting to pyramidal neurons, which could 
provide explanation why a negative modulator active at α5 
GABAA receptors might, at a distinct level of modulation of 
interneurons vs. pyramidal cells, produce an inhibitory effect.
The actual initiatives aimed to improve treatment of cognitive 
disruption, especially in schizophrenia, emphasize translational 
limitations of the current rodent cognitive models, including 
those used in the present study, and encourage more elaborate 
analysis of the obtainable results in a wider context of brain func-
tioning (Keeler and Robbins, 2011; Young et al., 2009). Although 
rather negative (e.g. the probe test in MWM did not confirm the 
acquisition phase results), our results correspond with the conclu-
sion of Young et al. (2012) that the animal models of cognitive 
disruption relevant to schizophrenia which demonstrate low to 
moderate ameliorating effects of pharmacological treatments 
may represent a “real life” scenario. In this vein, future pharma-
cological interaction studies with ligands which selectively mod-
ulate GABAergic neurotransmission and evidently do not affect 
the behavior of naïve animals, in parallel with standard antipsy-
chotic drugs, may add to the translational value of preclinical 
cognitive models.
In conclusion, the present results demonstrated a variable 
capability of negative modulation of α5 GABAA receptors to 
ameliorate the MK-801-induced deficits of learning and memory 
in rats, dependent on the cognitive task (declarative-like compo-
nent of memory was much more susceptible to prevention than 
spatial, while deficits in social recognition domain were resist-
ant), but also on the subtle changes in degree of receptor modula-
tion (dose dependence of beneficial effects of PWZ-029 was in 
an apparent inverted-U or even inverted J shape). While hyperlo-
comotion induced by MK-801 was amenable to only modest, if 
any, amelioration by PWZ-029, this ligand did not affect amphet-
amine-induced hyperactivity, suggesting low susceptibility of 
positive symptoms of schizophrenia to such a treatment. The fur-
ther research of potential clinical benefit of negative modulation 
of α5 GABAA receptors in schizophrenia should be focused on 
‘add-on’ prevention of deterioration of distinct cognitive domains 
which are in substantial number of patients resistant to the exist-
ing therapeutic options (Citrome, 2014).
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